Studies on the epidemiology of Escherichia coli infections. V. Factors influencing acquisition of specific serologic groups

The Journal of Clinical Investigation
R H WinterbauerR G PETERSDORF

Abstract

Stool carrier rates of Escherichia coli serogroups 4, 6, and 75 were determined on admission and discharge for 190 patients. Persons who were in the hospital 3 weeks or longer had an intestinal carrier rate of 46% compared to a rate of 28% in individuals who had no recent hospital contact. Treatment with broad spectrum antibiotics increased the susceptibility for acquisition of certain specific serologic groups. This was apparently not related to replacement of sensitive E. coli by drug-resistant forms. Studies were made to determine the environmental source for colonization of hospitalized patients and the risk of urinary infection in stool carriers of these strains. A survey of inanimate objects of medical and urological wards demonstrated infrequent isolation of 04, 06, and 075, indicating that extraintestinal foci were an unlikely source for hospital-acquired E. coli. Hemagglutination titers with determination of group-specific O antibody failed to demonstrate any deficiency in hospitalized patients who became colonized with certain coliforms. Similarly, no significant deficit in group-specific serum antibody was found in patients who were community carriers of E. coli 04, 06, or 075. Despite a high rate of acquisition of E...Continue Reading

References

Jan 1, 1966·Annual Review of Medicine·C M Kunin
Jul 1, 1961·Journal of General Microbiology·J PAPAVASSILIOU
Jan 1, 1962·The American Journal of Medicine·S E GROSSBERGI L BENNETT
Sep 1, 1962·The Journal of Clinical Investigation·M TURCK, R G PETERSDORF
May 2, 1963·The New England Journal of Medicine·K F AUSTEN, Z A COHN
Oct 1, 1962·Proceedings of the Society for Experimental Biology and Medicine·K L VOSTIL A RANTZ
Oct 1, 1963·Proceedings of the Society for Experimental Biology and Medicine·W C BRANCHEE D MASSEY
May 7, 1964·The New England Journal of Medicine·R M DONALDSON
Aug 1, 1964·Archives of Internal Medicine·J WILLIAMSONS P CHUEH
Dec 24, 1964·The New England Journal of Medicine·G F THOFRNTONL E CLUFF
Feb 1, 1965·The Journal of Clinical Investigation·R P KENNEDYR G PETERSDORF
Mar 3, 1960·The New England Journal of Medicine·A L KAITZ, E J WILLIAMS
Jun 21, 1962·The New England Journal of Medicine·C M KUNIN, N E HALMAGYI
Jan 1, 1962·Archives of Internal Medicine·L A RANTZ
Feb 1, 1962·The Journal of Experimental Medicine·J P SANFORDL L SOUDA
Jul 1, 1952·The Journal of Experimental Medicine·E NETERC E ARBESMAN

❮ Previous
Next ❯

Citations

Dec 1, 1972·The Journal of Hygiene·D van der WaaijJ M Vossen
Sep 1, 1969·The Journal of Hygiene·E I TannerD R Gamble
Dec 26, 1968·The New England Journal of Medicine·M J CarterJ C Cassady
Nov 20, 1969·The New England Journal of Medicine·W G JohansonJ P Sanford
Dec 17, 1970·The New England Journal of Medicine·D S Feingold
Mar 1, 1974·Annals of Surgery·S C SchimpffR B Hornick
Dec 6, 1969·British Medical Journal·E M CookeR A Shooter
Jan 1, 1980·Scandinavian Journal of Infectious Diseases. Supplementum
Nov 1, 1983·The American Journal of Physiology·C Meuli, J Müller
May 1, 1969·Applied Microbiology·J T ParisiR J Merlo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.